Paul L Bigliardi

View Scopus Profile

Paul L Bigliardi

Professor

 https://sandbox.orcid.org/0000-0003-4567-9080

Accepting PhD Students

1993 …2024

Research activity per year

Personal profile

Certifications and Licenses

Certifications, Licenses

 

  • Faculty license
  • Full Singapore Medical License

 

State of Minnesota, USA

Singapore Medical Council SMC

 

2017

2013

  • Certification of Specialist

    Accreditation Board Singapore

Dermatology SAB

2011

  • Board certification of Swiss

     Medical Association FMH

Allergology/Clinical Immunology

FMH

1999

  • Board certification of Swiss

     Medical Association FMH

Dermatology/Venereology

FMH

1998

  • Swiss Medical License

Ministry of Internal Affairs

Switzerland

1990

Professional Information

Academic Appointments

 

  • Professor in Dermatology
  • Associate Professor on

   Clinical Investigator track

 

University of Minnesota

National University of Singapore NUS Yong Loo Lin School of Medicine

 

2017 -

2011 - 2017

  • Guest lecturer for specialized wound nurses

Haute école supérieure HES, Geneva Switzerland

2008 - 2010

  • Privatdozent (A/Prof) and Maître d'Enseignement et de Recherche

University of Lausanne UNIL, Switzerland

2005 - 2011

  • Guest Professor for Dermatology

ETH Zurich, Switzerland

Department of Pharmacy

2004 - 2010

  • Guest Professor for specialized wound nurses

H+ Swiss Hospital Organisation, Aarau, Switzerland

2003 - 2010

  • Privatdozent (A/Prof)

University of Basel, Switzerland

Department of Dermatology

2003 - today

 

Academic Administrative Appointments

 

  • Director of Clinical Research Unit for Skin, Allergy and Regeneration CRUSAR

 

Institute of Medical Biology, Agency for Science and Technology, A*STAR, Singapore

 

2013 -  2017

  • Senior PI Experimental Dermatology Group

 

Institute of Medical Biology, Agency for Science and Technology, A*STAR, Singapore

2011 - 2017

  • Director of Academic Dermatology and Allergology

National University Hospital Singapore NUHS, University Medicine Cluster

2011 - 2017

  • Head and clinical PI of Neurodermatology laboratory

University of Lausanne, Switzerland Department of Dermatology

2005 - 2010

  • Head and clinical PI of Neurodermatology laboratory

University of Basel, Switzerland, Department of Research/Dermatology

1999 - 2005

 

Clinical/Hospital Appointments

 

  • Director of Dermato-Allergy clinic

 

  • Senior consultant and Director of adult allergy clinic 

 

Department of Dermatology, University of Minnesota/UMP

Department of Rheumatology, National University Hospital Singapore NUHS

 

2017 -

 

2012 - 2017

  • Médecin adjoint (senior consultant) and Director of Outpatient and Wound and Dermato-allergy clinic

Department of Dermatology, University Hospital Lausanne, CHUV Switzerland

 

2005 - 2011

  • Head of Dermatology & Allergology and private clinic

Kantonsspital Schaffhausen, Switzerland, Dept of Medicine

1999 - 2005

Intellectual Property

Patents

 

Use of selective delta-opioid receptor Modifiers and specific sensory receptor ligands. Inventors: Bigliardi-Qi M and Bigliardi PL. Pending patent (PCP filed 02.2014; No PCT/SG2014/000025)

Multi-spectral calibrated light source for long term cell culture study. Inventors: Paul Lorenz Bigliardi (IMB); CHUA Soo Jin (NUS; IMRE); TAY Chuan Beng (NUS); WANG Ben Zhong (IMRE); Mei Bigliardi-QI (IMB); Institutions: IMB, IMRE, NUS, Provisional SG Patent application filed 6.3.2015; Application No: 10201501747P; IMB/P/08796/00/SG; ILO Ref: 15030N-SG/PRV

Specific targeting of melanocytes and melanoma cells by photodynamic therapy using ligated photosensitizers directed against MC-1 receptors. Inventors: Paul Lorenz Bigliardi; Mei Bigliardi-Qi; Brandon Burkett, Bhimsen Rout, Aakansha Pant. PCP filed 24.8.2015; ETPL Ref: IMB/P/09104/00/SG, SG application number 10201506686W

Thin Film Deposited Inorganic Metal Oxide as a Selective Substrate for Mammalian Cell Culture

Inventors: Dykas Michal Marcin, Poddar Kingshuk, Thirumalai Venky Venkatesan, Krishnan Kutty Viknish, Bigliardi Paul, Bigliardi Mei. ILO Ref: 15151N-US/PRV, ETPL Ref: IMB/Z/09162, US prov 62/285,222

Microfluidic chip system for standardized, reliable and high-throughput screening and analysis

Inventors: Paul Lorenz Bigliardi, Zhiping Wang, Wu Ruige, Massimo Alberti, Wu Bo, Mei Bigliardi-Qi, Sriram Gopu, Srinivas Ramasami, Yuri Dancik. ETPL Ref: IMB/Z/09559

Developing Novel Non-Toxic, Non-Allergenic p-phenylenediamine Analogues for Hair Dyes and Temporary Tattoos

Inventors: Pastorin Giorgia, Bigliardi Paul L, Valiyaveettil Suresh, Venkatesan Gopalakrishnan, Sinha Arup, Dancik Yuri H, Bigilardi-Qi M. ILO Ref: 2017-101; ETPL Ref:

Submitted: Systems and Methods for analyzing cutaneous conditions

Inventors: Massey Jeremy M, Alam Syed H, Bigliardi Paul L, Bigliardi-Qi Mei; applicant Ref JAT/AS/sng/17004948, application No 10201706752X

Publications

Publications [not included poster presentations]

 

#

Peer-reviewed publications

1

Grando SA, Cabrera R, Hostager BS, Bigliardi PL, Blake JS, Herron MJ, Dahl MV and Nelson RD: Computerized microassay of keratinocyte cell-plastic attachment and proliferation for assessing net stimulatory, inhibitory and toxic effects of compounds on nonimmortalized cell lines. Skin Pharmacol 6: 135-47, 1993

2

Bigliardi PL, Herron MJ, Nelson RD and Dahl MV: Effects of detergents on proliferation and metabolism of human keratinocytes. Exp Dermatol 3: 89-94, 1994

3

Grando SA, Zelickson BD, Kist DA, Weinshenker D, Bigliardi PL, Wendelschafer-Crabb G, Kennedy WR and Dahl MV: Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization. J Invest Dermatol 104: 95-100, 1995

4

Bigliardi PL, Bigliardi-Qi M, Büchner S and Rufli T: Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 111: 297-301, 1998

5

Moins-Teisserenc HT, Gadola SD, Cella M, Dunbar PR, Exley A, Blake N, Baykal C, Lambert J, Bigliardi P, Willemsen M, Jones M, Büchner S, Colonna M, Gross WL, Cerundolo V and Baycal C: Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 354: 1598-603, 1999

6

Bircher AJ, Bigliardi P and Yilmaz B: Anaphylaxis resulting from selective sensitization to Americana grapes. J Allergy Clin Immunol 104: 1111-3, 1999

7

Bircher AJ, Bigliardi P, Langauer Messmer S and Surber C: Occupational airborne contact dermatitis from diphencyprone in a pharmacy employee. Contact Dermatitis 41: 52, 1999

8

Bigliardi-Qi M, Bigliardi PL, Büchner S and Rufli T: Characterization of mu-opiate receptor in human epidermis and keratinocytes. Ann N Y Acad Sci 885: 368-71., 1999

9

Bircher AJ, Bigliardi P, Zaugg T and Makinen-Kiljunen S: Delayed generalized allergic reactions to corticosteroids. Dermatology 200: 349-51, 2000

10

Bigliardi-Qi M, Bigliardi PL, Eberle AN, Büchner S and Rufli T: beta-endorphin stimulates cytokeratin 16 expression and downregulates mu-opiate receptor expression in human epidermis. J Invest Dermatol 114: 527-32, 2000

11

Bigliardi PL, Büchner S, Rufli T and Bigliardi-Qi M: Specific stimulation of  migration of human keratinocytes by u-opiate receptor agonists. J Recept Signal Transduct Res 22: 191-199, 2002

12

Bigliardi PL, Sumanovski LT, Büchner S, Eberle AN, Rufli T and Bigliardi-Qi M: Different expression of u-opiate receptor in chronic and acute wounds and the effect of beta-endorphin on TGF-beta type II receptor and cytokeratin 16 expression. J Invest Dermatol 120: 145-152, 2003

13

Bigliardi PL, Izakovic J, Weber JM and Bircher AJ: Anaphylaxis to the carbohydrate carboxymethylcellulose in parenteral corticosteroid preparations. Dermatology 207: 100-103, 2003

14

Bigliardi PL, Braschler C, Kuhn P, Sigrist J, Büchner S and Rufli T: Unilateral aplasia cutis congenita on the leg. Pediatric Dermatol 21: 454 –457, 2004

15

Bigliardi-Qi M, Sumanovski L, Büchner S, Rufli T and Bigliardi PL: u-opiate receptor and beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 209:183-189,2004

16

Bigliardi-Qi M, Lipp B, Sumanovski LT, Büchner S and Bigliardi PL: Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitits. Dermatology 210: 91-99, 2005

17

Bigliardi PL and Bigliardi-Qi M: Controversies in Experimental Dermatology: How best to treat that nasty itch – From new insights into the neuroimmunology, neuroendocrinology and neurophysiology of pruritus to novel therapeutic approaches. Exp Dermatol 14: 236-237, 2005

18

Bigliardi PL: PRURIT: causes, diagnostic et traitement. Revue Medicale Suisse 2: 1115-21, 2006

19

Bigliardi-Qi M, Gaveriaux-Ruff C, Zhou H, Hell C, Bady P, Rufli T, Kieffer B and Bigliardi PL: Deletion of delta opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 74: 174-185, 2006

20

Bigliardi PL: Ursachen, Diagnose und Therapie von Pruritus. Aktuelle Dermatologie 32:468-473, 2006

21

Bigliardi-Qi M, Gaveriaux-Ruff C, Pfaltz K, Bady P, Baumann T, Rufli T, Kieffer B and Bigliardi PL: Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings and itch behavior. J Invest Dermatol 127: 1479-88, 2007 

22

Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S and Bigliardi-Qi M: Treatment of chronic pruritus in atopic dermatitis with topically applied opiate-receptor antagonist Naltrexone: Open pilot study and randomized, placebo-controlled, cross-over trial. J Am Acad Dermatol 56: 979-88, 2007

23

Bigliardi PL, Raffoul W and Berger MM: Toxic Epidermal Necrolysis. Revue Medicale Suisse 3: 1112-8, 2007

24

 Bigliardi PL: Wenn sich der Patient die Haut vom Leibe kratzen könnte – was hilft? Dermatologie Praxis 2: 24-26, 2007

25

Bigliardi PL: Pruritus – Therapie bei verschiedenen Grunderkrankungen Dermatologie Praxis 32: 20-22, 2007

26

Bigliardi PL, Gabard B and Vogel-Kahmann I: Update – Kortikosteroide zur lokalen Anwendung auf der Haut. Pharmakritik 30 : 29-36, 8/9/2008.

27

Bigliardi-Qi M, Noblesse E, Chen ZQ, Gao FL, Bigliardi PL and Bonte F: Role of Opioid Receptors in Skin. Chinese Journal of Dermatology 41:8; 6-8, 2008

28

Bigliardi PL, Gaveriaux-Ruff C, Tobin D and Bigliardi-Qi M: Opioids and the skin – where do we stand? Viewpoint-article. Experimental Dermatology 18:424-430, 2009

29

Bigliardi PL and Panizzon R: Hautkrankheiten mit Licht heilen. Dermatologie Praxis, 5: 10-13, 2009

30

Bigliardi-Qi M, Gaveriaux-Ruff C, Neumann C, Kieffer B and Bigliardi PL: The role of skin opioid receptor system in itch. Acta Dermato-Venereologica 89:6, 700, 2009

31

Grasset N, Raffoul W and Bigliardi PL: Pansements Bioactifs (nouveautés en medecine 2009). Revue Medicale Suisse 6:354-7, 2010

32

Grouzmann E, Bigliardi PL, Appenzeller M, Pannatier A, Buclin T: Substance P induced skin inflammation is not modulated by a single dose of Sitagliptin in human volunteers; J Biol Chem 392:217-21, 2011

33

Spring P and Bigliardi P: Chronic hand eczema, conventional and new treatments; Rev Med Suisse 4:8: 736-742, 2012

34

Peltzer N, Bigliardi P and Widmann C: UV-B induces cytoplasmic survivin expression in mouse epidermis; J Dermatol Sci, 67:3: 196-199, 2012

35

Khalil H, Peltzer N, Walicki J, Yang JY, Dubuis G, Gardiol N, Held W, Bigliardi P, Marsland B, Liaudet L and Widmann C: Caspase-3 protects stressed organs against cell death; Mol Cell Biol, 32:22: 4523-4533, 2012

36

Spring P, Angelillo-Scherrer Aand Bigliardi PL: Chronic Idiopathic Urticaria successfully treated by anticoagulant drugs. Eur J Dermatol, 22:6:788-90, 2012

37

Bigliardi PL, Neumann C, Teo YL, Pant A and Bigliardi-Qi M: Activation of the delta-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration. Br J Pharmacol, 172:2: 501-14, 2015

38

Bigliardi PL: Pruritus im Alter (Pruritus senilis). Dermatologie Praxis, Vol 24, No2, 2014

39

Thalayasingam M, Allameen NA, Soh JY, Bigliardi PL, Van Bever H and Shek LP: Wheat-Dependent Exercise-Induced Anaphylaxis: a retrospective case review from a tertiary hospital. Postgraduate Medical Journal, Vol 90/1067, p 488-92, 2014

40

Neumann C, Bigliardi-Qi M, Widmann Cand Bigliardi PL: The δ-Opioid Receptor Affects Epidermal Homeostasis via ERK-Dependent Inhibition of Transcription Factor POU2F3. J Invest Dermatol, 135:2, 471-80, 2015

41

Cerny D, Shin A, Haniffa M, Bigliardi PL, Tan BK, Lee B, Poidinger M, Tan EY, Ginhoux F and Fink K: Selective susceptibility of Human Skin Antigen Presenting Cells to Productive Dengue Virus Infection. PLOS Pathogens, Published: December 04, 2014; DOI: 10.1371/journal.ppat.1004548

42

Bigliardi-Qi M and Bigliardi PL: The role of opioid receptors in migration and wound recovery in-vitro in cultured human keratinocytes and fibroblasts. Methods Mol Biol, 1230, p273-7, 2015

43

Santosa E, Andiappan A, Rotzschke O, Wong HC, Marti HP, Chang A, Bigliardi-Qi M,Wang DY and Bigliardi PL: Evaluation of the applicability of the Immuno-solid-phase allergen chip (ISAC) assay in atopic patients in Singapore. Clinical and Translational Allergy, 5:9, 2015

44

Yik JH, Bigliardi PL, Sebastin SJ, Cabucanca NJ and Krishna L: Pyoderma Gangrenosum Mimicking Early Acute Infection Following Total Knee Arthroplasty. Annals Acad Med Singapore, Vol 44:4, 150-51, 2015.

45

Gopu S, Bigliardi PL & Bigliardi-Qi M: Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro. European J Cell Biol, Vol 94, 483-512, 2015

46

Ford S, Bigliardi PL, Sardella T, Urich A, Burton NC, Kacprowicz M, Bigliardi M, Olivo M and Razansky D. Structural and functional analysis of intact hair follicles and pilosebaceous units by volumetric multispectral optoacoustic tomography. J Invest Dermatol, 12. 2015 (ISSN 1523-1747 (Electronic), DOI 10.1016/j.jid.2015.09.001)

47

Dancik Y, Bigliardi PL, Bigliardi-Qi M and Jaworska J: What happens in the skin? Integrating skin permeation kinetics into studies of developmental and reproductive toxicity following topical exposure. Reproductive Toxicology, 58: p252-81, Dec 2015

48

Sriram G, Dykas M, Venkatesan Th, Bigliardi-Qi M and Bigliardi PL: Reconstructing human skin equivalents on fibrin-based dermal matrix. Materials Today, 2016; doi:10.1016/j.mattod.2016.01.015

49

Chew EG, Tan JH, Bahta AW, Ho BS, Liu X, Lim TC, Sia YY, Bigliardi PL, Heilmann S, Wan AC, Nothen MM, Philpott MP, Hillmer AM: Differential expression between human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for androgenetic alopecia. J Invest Dermatol, 2016/04/10; S0022-202X(16)31024-7. doi: 10.1016/j.jid.2016.03.032.

50

Bigliardi PL, Dancik Y, Neumann C and Bigliardi-Qi M: Opioids and skin homeostasis, regeneration and ageing – What’s the evidence? Viewpoint Article. Exp Dermatol, doi 10.1111/exd.13021, 2016

51

Chew EGY, Ho BSY, Ramasamy S, Dawson T, Tennakoon C, Liu X, Leong WMS, Yang SYS, Lim SYD, Jaffar H, Hillmer AM, Bigliardi-Qi M and Bigliardi PL: Whole transcriptome discovery study identifies altered oxidation-reduction state in hair follicles of androgenetic alopecia patients. Br J Dermatol, doi: 10.1111/bjd.14767, 2016

52

Kutty VK, Bigliardi PL, Dykas MM, Pomp O, Venkatesan T and Bigliardi-Qi M: Human peripheral nerve fibers form complex physical interactions with human keratinocytes in a novel 2D culture model. Exp Dermatol, ISSN: 1600-0625/0906-6705; DOI: 10.1111/exd.13181, 2016 (pictures used for cover illustration of March issue 2017)

53

Pei Chern Toh P, Bigliardi-Qi M, Yi Yap AM, Sriram G and Bigliardi PL: Peropsin exists in human skin and plays a role in specific phototransduction of violet light in keratinocytes. Exp Dermatol; ISSN: 1600-0625/0906-6705; doi:10.1111/exd.13226; 09. 2016

54

Teo SL, Santosa A and Bigliardi PL: Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis overlap to an anti-histamine – Fexofenadine. J Invest All Clin Immunol, 27 [3], DOI 10.18176 / jiaci.0158, 2017

55

Jiang J, Ho Siu-Yin B, Ge Q, Xie XM, Yu Z, Bigliardi PL and Bigliardi-Qi M: Aging in hair follicle stem cells and niche microenvironment. J Dermatol. DOI 10.1111/1346-8138.13897, 2017

56

Alberti M, Dancik Y, Gopu S, Wu B, Teo YL, Feng Z, Bigliardi-Qi M, Wu R, Wang Z and Bigliardi PL: Multi-chamber microfluidic platform for high precision skin permeation testing. Lab chip, Royal Society of Chemistry, DOI 10.1039/c6lc01574c, 2017

57

Eberle AN, Rout B, Bigliardi-Qi M and Bigliardi PL: Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions. Curr Med Chem, DOI 10.2174 / 092986732466617060510594205, 2017

58

Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon JK, Wa CTC and Villa MA: Povidone Iodine in wound healing: review of current concepts and practices. Int J Surgery, 44:260, DOI 10.1016/j.ijsu.2017.06.073; 2017

59

BigliardiPL, Langer S, Cruz JJ, Sang WK, Harikrishna N, Gulapar S:An Asian Perspective on Povidone Iodine in Wound Healing. Dermatology, DOI: 10.1159/000479150; 2017

60

Leong C, Bigliardi PL (co-first author), Gopu S, Bijin VA, Connolly J, Bigliardi-Qi M: Physiological doses of red light induce IL-4 release in co-cultures between human keratinocytes and immune cells. J Photochemistry and Photobiology; DOI: 10.1111/php.12817; 2017

61

Rout B and Bigliardi PL: Pattern-Generating Unimolecular Sensors: For Future Differential Sensing and Molecular Computing. Synlett; 28:9:1005-1010, DOI: 10.1055/s-0036-1588721; 2017

62

Bigliardi PL, Rout B, Pant A, Kutty V, Eberle A, Burkett B and Bigliardi-Qi M: Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy. Scientific Reports, 7: 15750, DOI:10.1038/s41598-017-15142-w; 2017

63

Rout B, Bigliardi-Qi M and Bigliardi PL: An expedient multiple information processing pattern-generating chromophores. Sensors and Actuators B: Chemical, 251: 164-170, DOI: 10.1016/j.snb.2017.05.046; 2017

64

Leong C, Neumann C; Ramasamy S, Rout B, Lim Y, Bigliardi-Qi M, Bigliardi PL: Investigating the dynamics of endogenous μ-opioid receptors in human keratinocytes as pharmacological targets using fluorescent opioid ligand. PLOS one ; Vol 12, epub DOI: 10.1371/journal.pone.0188607, 2017

65

Alberti, M, Gopu S, Dancik YH, Wu B, Wu R, Ramasamy S, Bigliardi-Qi M, Bigliardi PL* and Wang Z* (* co-last authors): Full thickness human skin-on-chip with enhanced epidermal morphogenesis and barrier function. Accepted for publication in Materials Today 11/22/2017 (MATTOD_2017_317)

66

Dancik YH, Gopu S, Rout B, Bigliardi-Qi M and Bigliardi PL: Physical and compositional analysis of differently cultured 3D skin equivalents by confocal Raman spectroscopy. Accepted for publication in Analyst 01.2018

Research interests

RESEARCH ACTIVITIES and SCIENTIFIC INTERESTS

           

Singapore’s initiative for translational research inspired me to propose and create the Clinical Research Centre for Skin, Allergy and Regeneration (CRUSAR). The CRUSAR establishment was the cornerstone of a larger, nation-wide initiative for skin translational research totalling. CRUSAR had the mission to develop and test concepts for new designs of clinical studies with smaller cohorts, but with accurate and objective measurements. This includes novel 2D and 3D organotypic epithelial models for studies on metabolism, absorption and toxicology using microfluidic chips and 3D printing techniques and cross-validation of the in-vitro data by non-invasive in-vivo measurements. These developments also include analytical tools and imaging devices such as Raman Spectroscopy, hyperspectral imaging, multispectral optoacoustic tomography and comparison with state-of-the-art molecular biological methods such as full transcriptomic RNA and miRNA analysis. Trials validated this concept and the results were published or will be published in various leading Dermatology Journals. Our research focus in the last 10 years was in following topics and we intend to pursue in future this kind of multidisciplinary and applied research at the University of Minnesota:

 

Peripheral Opioid receptor research and Neurodermatology: Key opinion leaders of Opioid receptor system in skin and its effects on peripheral sensation (pain and itch), nerve regeneration and skin homeostasis, epidermal differentiation, adhesion, migration and their application in wound healing, ageing, modulation of cutaneous circadian rhythm and tumour growth. Studying the role of peripheral nervous system and various neuropeptides/neurotransmitters in skin sensation, wound healing and interactions between peripheral nerves endings and skin cells using co-culture 2D and 3D models and electrophysiology, molecular biology and proteomics. Recognizing skin cells at the forefront of peripheral sensation and investigating the role of sensory receptors (e.g. olfactory, taste, opsin, touch) and modulating effects of opioids in keratinocytes in receiving and transmitting different shades of sensation. This includes investigations on the bi-directional interactions and role of Neuro-Immuno-Skin axis in skin pathophysiology and has potential in peripheral treatment of pain with topical opioids without addiction.

Clinical and Translational Research: novel designs and executions of clinical trials in skin, allergy and wound healing and integration of innovative non-invasive laser devices (e.g. Raman spectroscopy and photoacoustics MSOT) to study healthy and diseased human skin.

Skin Toxicology and Transcutaneous Absorption: combine and cross-validate information’s from in-vitro human 3D skin models (organotypic cultures) on microfluidic chips with in-vivo studies using novel laser devices and evaluating skin toxicology, transcutaneous absorption and metabolism of various compounds in skin as well as examine trans-epithelial vector absorption and the impact of genetic alteration via CRISPR for real time toxicology on the organotypic skin. This model gives opportunities for study diseased skin and pathophysiological processes (e.g. epidermolysis bullosa, wound healing or skin cancers such ad melanoma). 3D printing technologies can be integrated into this epithelia-on-chip model.

Allergology and Immunology: drug induced allergies and intolerances; immunologic interactions with microbiome in the skin; ethnic differences in allergic reactions; effects of pollution on allergens and immune system; the role of the skin barrier in skin irritation and sensitization to microbial and contact allergens.

Wound healing: biofilm and microbiome, wound infections; wound disorders; scar formation; novel wound dressings, allografts; cross-talk between immune cells, nerves and epidermal cells in wound healing

Photobiology: study immediate and delayed effects of various light qualities (from UV to Infrared) on skin cells in-vitro (including specific opsin receptors); design novel targeted photosensitizers for photodynamic therapy (e.g. for superficial melanomas); develop novel devices to study standardized and reproducible effects of defined wave lengths on skin cells in-vitro and human skin in-vivo

Hair biology: differential expression of genes and proteins in healthy and diseased scalp skin; role of micro-RNA in hair biology and discovery of a new pathway involved in miniaturization of hair (PDG1a/PPARg)

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Research interests

  • Neurodermatology
  • allergology
  • opioid receptors
  • skin sensation (itch/pain)
  • drug allergies/intolerances
  • wound healing
  • skin pharmacology/toxicology
  • 3D epithelial cultures in microfluidic chips
  • 3D printing
  • non-invasive imaging
  • clinical trials

Fingerprint

Dive into the research topics where Paul L Bigliardi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles
View full fingerprint

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Explore network further
View all 88 Research outputs